New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated April 30, 2025
1W % 1M % 3M % 1Y %

Key Metrics

Shape

  • Market Cap

  • Shares Outstanding

  • Share in Float

  • Dividende

  • Earning Date

    No Data

  • Price Target

  • Average Volume

  • Beta

  • Range

  • Industry

  • Website

  • Sector

Fundamentals

Shape

Relative Strength

Shape

DXR

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$2M

Shape3079%

2025-Revenue

$0.08

Shape124%

2025-EPS

$2M

Shape153%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.20

arrow
arrow

N/A

-0.85
vs 0.1

Q4.20

arrow
arrow

+203%

0.23
vs -0.22

Q2.21

arrow
arrow

N/A

-0.19
vs -0.85

Q4.21

arrow
arrow

+242%

0.78
vs 0.23

Q2.22

arrow
arrow

N/A

-0.22
vs -0.19

Q4.22

arrow
arrow

+4%

0.81
vs 0.78

Q2.23

arrow
arrow

N/A

-0.32
vs -0.22

Q4.23

arrow
arrow

-12%

0.72
vs 0.81

Q2.24

arrow
arrow

N/A

-0.34
vs -0.32

Q3.24

arrow
arrow

N/A

1.54
vs NA

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.20

arrow
arrow

-22%

145.5K  vs 187.2K

Q2.21

arrow
arrow

+6%

125.7K  vs 118.9K

Q4.21

arrow
arrow

+5%

152.4K  vs 145.5K

Q2.22

arrow
arrow

+8%

135.2K  vs 125.7K

Q4.22

arrow
arrow

-37%

96.4K  vs 152.4K

Q2.23

arrow
arrow

-40%

81K  vs 135.2K

Q4.23

arrow
arrow

-14%

82.4K  vs 96.4K

Q2.24

arrow
arrow

-11%

71.8K  vs 81K

Q3.24

arrow
arrow

NA

67.4K  vs NA

Q4.24

arrow
arrow

-23%

63.3K  vs 82.4K

Return on EquityShape

status-upQoQ

Q2.21

arrow
arrow

-11%

-0.11
vs 0.12

Q4.21

arrow
arrow

+30%

0.3
vs -0.11

Q2.22

arrow
arrow

-9%

-0.09
vs 0.3

Q4.22

arrow
arrow

+24%

0.24
vs -0.09

Q2.23

arrow
arrow

-10%

-0.10
vs 0.24

Q4.23

arrow
arrow

+10%

0.1
vs -0.10

Q2.24

arrow
arrow

-5%

-0.05
vs 0.1

Q4.24

arrow
arrow

NA

NA
vs -0.05

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

4

4
vs 5

-20%

Q2.23

arrow
arrow

5

5
vs 4

25%

Q3.23

arrow
arrow

5

5
vs 5

NA

Q4.23

arrow
arrow

6

6
vs 5

20%

Q1.24

arrow
arrow

7

7
vs 6

17%

Q2.24

arrow
arrow

6

6
vs 7

-14%

Q3.24

arrow
arrow

9

9
vs 6

50%

Q4.24

arrow
arrow

9

9
vs 9

NA

Earnings Growth

Latest News

DXR

globenewswire.com

8 hours ago

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
DXR

globenewswire.com

8 hours ago

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
DXR

globenewswire.com

8 hours ago

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
DXR

globenewswire.com

8 hours ago

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo
DXR

globenewswire.com

8 hours ago

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
DXR

seekingalpha.com

21 hours ago

Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript